NEW YORK, Feb. 6 - Genaissance Pharmaceuticals on Wednesday said it has tapped Japan's Intec Web & Genome Informatics Corporation to market all of its pharmacogenomics applications and products to pharmaceutical, diagnostic, and biotechnology companies in that country.
Financial terms of the agreement were not disclosed.
Genaissance's efforts to strike out in Japan will give it access to the second-largest pharma market in the world and the approximately 600 pharma and biotech companies there.
"With Intec W&G as our Japanese sales representative, Genaissance is expanding its potential market reach to a country that is second only to the US in pharmaceutical sales," Kevin Rakin, president and CFO of Genaissance, said in a statement.
Munehiro Sueoka, president of Intec W&G, added: "Here in Japan, we intend to replicate the success Genaissance has achieved with US and European biopharmaceutical companies. We view the collaboration as an opportunity to expand our leadership in providing the best new technologies to our clients in Japan."